AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Elahere (mirvetuximab soravtansine) by Year
Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%)
AbbVie Elahere (mirvetuximab soravtansine): 27.2% in FY2025.
Latest, FY2025
27.2%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04)
Where the FY2025 figure comes from
“|| Elahere | 607 | 83 | 690 | 27.2”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.2% | – | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) (%), annual FY2025–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.